Adding Pembrolizumab to Docetaxel Does Not Significantly Improve Outcomes in Patients with Previously Treated mCRPC By Ogkologos - April 9, 2025 705 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KEYNOTE-921 study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR FDA Grants Accelerated Approval to the Combination of Avutometinib and Defactinib... May 30, 2025 County Denies Immunocompromised Employee’s Request to Work from Home During COVID-19 March 17, 2020 ESMO Gynaecological Cancers Congress 2023 February 10, 2023 A tribute to Professor Gordon McVie February 18, 2021 Load more HOT NEWS Cancer Immunotherapies Don’t Work for Everyone: HLA Gene May Explain Why Advancing Cancer Prevention: A Conversation with NCI’s Dr. Philip Castle Bringing the Cancer Community Back Together at ASCO Annual Meeting: Why... Repotrectinib Expands Treatment Options for Lung Cancers with ROS1 Fusions
